Neuroblastoma Market Report 2025

This Neuroblastoma market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The neuroblastoma market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth observed during the historic period can be attributed to factors such as the rising prevalence of neuroblastoma, increased research and development focused on pediatric neuroblastoma treatments, a higher incidence of childhood cancer, and growing government funding and support.

The neuroblastoma market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth projected for the forecast period can be attributed to factors such as rising government funding, a higher incidence of the disease, an increasing emphasis on early detection, a growing prevalence of genetic mutations, and advancements in research and understanding. Key trends expected during this period include the development of drugs targeting specific molecular pathways, innovations in non-invasive imaging technologies, progress in gene-editing technologies, a greater focus on personalized treatment approaches, and the development of radiolabeled compounds.

The growth of the neuroblastoma market is expected to be driven by the rising incidence of childhood cancer. Childhood cancer refers to a group of cancers that primarily affect children and adolescents, often targeting organs such as the brain, blood, and bones, and requiring specialized treatment methods. This increase in childhood cancer cases can be attributed to several factors, including advancements in diagnostic techniques, greater awareness, environmental exposures, genetic factors, and progress in medical research. Neuroblastoma treatments offer targeted therapies for childhood cancer, allowing for early intervention that reduces the risk of recurrence and improves the prognosis for young patients. For example, in May 2024, the American Cancer Society, a US-based professional organization, projected that around 9,620 children under the age of 15 in the United States would be diagnosed with cancer in 2024, up from 5,290 cases in 2023. As a result, the rising incidence of childhood cancer is a key factor driving the growth of the neuroblastoma market.

Leading companies in the neuroblastoma market are concentrating on developing innovative therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to more effectively and safely target cancer cells. These antibodies are engineered to specifically target the GD2 molecule on cancer cells while minimizing immune rejection by incorporating human components. For example, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced that it had in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. This antibody is designed for the treatment of newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. According to the agreement, Renaissance has obtained exclusive rights to develop, manufacture, and commercialize Hu14.18 in key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, completed the acquisition of Apeiron Biologics AG for $100 million. Through this acquisition, Ligand gains royalty rights to Qarziba and aims to enhance its commercial royalty portfolio by adding a high-value immunotherapy for high-risk neuroblastoma. This move is expected to drive growth by generating long-term, predictable revenue from a diverse range of key products. Apeiron Biologics AG, based in Austria, is a biotech company specializing in the development of immunotherapies for neuroblastoma.

Major players in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroblastoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Neuroblastoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neuroblastoma is a type of cancer that predominantly affects children, originating from immature nerve cells called neuroblasts. This cancer often develops in the adrenal glands, which sit atop the kidneys, but it can also occur in other regions of the abdomen, chest, neck, or pelvis. Symptoms associated with neuroblastoma may include abdominal pain, swelling, fatigue, and in some cases, bone pain or the presence of lumps.

The primary product types for treating neuroblastoma include tablets, vaccines, and others. Tablets are solid oral dosages containing active ingredients, binders, and fillers, used in the treatment of neuroblastoma to administer chemotherapy or targeted therapy drugs. Treatment options for neuroblastoma include chemotherapy, immunotherapy, and other approaches, which are distributed through various channels, both online and offline. These treatments are typically used in hospitals and clinics.

The neuroblastoma market research report is one of a series of new reports that provides neuroblastoma market statistics including the neuroblastoma industry global market size regional shares competitors with the neuroblastoma market share detailed neuroblastoma market segments market trends and opportunities and any further data you may need to thrive in the neuroblastoma industry. This neuroblastoma market research report delivers a complete perspective of everything you need with an in-depth analysis of the current and future scenarios of the industry.

The neuroblastoma market consists of revenues earned by entities by providing services such as diagnosis and imaging, oncology treatment, and stem cell transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroblastoma market also consists of sales of radiopharmaceuticals, monoclonal antibodies, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.